Yield increases in intact influenza vaccine virus from chicken allantoic fluid through isolation from insoluble allantoic debris

被引:10
作者
Hughes, Kenneth
Zachertowska, Alicja
Wan, Simmy
Li, Lily
Klimaszewski, Damian
Euloth, Michelle
Hatchette, Todd F.
机构
[1] Microbix Biosyst Inc, Toronto, ON M8V 3A8, Canada
[2] Queen Elizabeth II Hlth Sci Ctr, Div Microbiol, Dept Pathol & Lab Med, Halifax, NS B3H 1V8, Canada
关键词
influenza; vaccine; yield; embryonated; eggs;
D O I
10.1016/j.vaccine.2007.03.017
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A yield enhancement technology for use in influenza vaccine manufacturing has been developed to maximize the recovery of influenza virus from allantoic fluid of virus-infected chick embryos; the standard raw material for influenza vaccine. Virus associated with amorphous debris in the allantoic fluid can be dissociated from the debris and recovered, thereby increasing viral yield. Dissociation can be achieved by subjecting the virus-debris complex to conditions of increased ionic strength at defined pH. Multifold increases in viral yield per ml of allantoic fluid were observed. The degree of yield enhancement is strain-specific, however, increases were observed in all type A and type B influenza strains tested. The heightened influenza virus recoveries can facilitate rapid vaccine manufacture, with increased numbers of doses produced, and may become essential at a time of influenza pandemic. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4456 / 4463
页数:8
相关论文
共 22 条
[1]  
[Anonymous], 2006, CAN PAND INFL PLAN H
[2]   The growth of attenuated influenza vaccine donor strains in continuous cell lines [J].
Audsley, JM ;
Tannock, GA .
JOURNAL OF VIROLOGICAL METHODS, 2005, 123 (02) :187-193
[3]  
BENEDICTUS JD, 1982, Patent No. 4327182
[4]  
CANO FR, 1976, Patent No. 4000257
[5]   Comparison of four clinical specimen types for detection of influenza A and B viruses by optical immunoassay (FLU OIA test) and cell culture methods [J].
Covalciuc, KA ;
Webb, KH ;
Carlson, CA .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (12) :3971-3974
[6]  
EICHHORN U, 2002, Patent No. 02097072
[7]  
*EMEA, 1997, CPMPBWP24196
[8]  
Harper SA, 2004, PREVENTION CONTROL I
[9]   Dose sparing with intradermal injection of influenza vaccine [J].
Kenney, RT ;
Frech, SA ;
Muenz, LR ;
Villar, CP ;
Glenn, GM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (22) :2295-2301
[10]   A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European community for immunogenicity, in children, adults and the elderly [J].
Lina, B ;
Fletcher, MA ;
Valette, M ;
Saliou, P ;
Aymard, M .
BIOLOGICALS, 2000, 28 (02) :95-103